New Jersey Wins Nearly $2.5mill in False Marketing Settlement

New Jersey's Attorney General John J Hoffman announced that the state will receive $2.45 million settlement with pharmaceutical giant GlaxoSmithKline. 

GlaxoSmithKline illegally promoted the use of their pharmaceutical products for uses that were not approved by industry: they initially marketed Advair for treating mild asthma rather than severe cases, and antidepressant Paxil as safe for children. 

"This settlement is important to protecting New Jersey consumers because it calls for the use of only clear, objective, well-supported clinical information in the promotion of these GlaxoSmithKline medications," Hoffman said in a press release. 

GlaskoSmithKline will pay $105 million total to New Jersey, 43 other states, and the District of Columbia, according to a press release from the Attorney General's office. 

The settlement also be requires the company to reform their marketing through accurate written and oral claims and through information consistent to the Food and Drug Administration's approval. They will also be prohibited from presenting findings from studies that are "inadequate in design, scope, or conduct," according to the settlement.